Advanced Gastric Cancer With Serosal Invasion Clinical Trial
Official title:
Prospective Randomized Multicenter Phase III Trial of Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer
Intraperitoneal chemotherapy as an adjuvant treatment modality is designed to eradicate
intraperitoneal free tumor cells that can be a source of peritoneal carcinomatosis. Although
we have not reached unanimous consensus, favorable reports on the outcome of intraperitoneal
chemotherapy have been published.
In this study, we review the clinicopathological characteristics of patients and effects of
early postoperative intraperitoneal chemotherapy (EPIC) on overall and gastric
cancer-specific survival and patterns of recurrence of gastric cancer patients with
macroscopic serosal invasion.
The aim of this study is to evaluate the impact of intraperitoneal chemotherapy on overall
and disease free survival of advanced gastric cancer patients with serosal invasion after
potentially curative surgery.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment